A claims-based analysis of secondary progressive multiple sclerosis (SPMS): Prevalence, demographics, and costs

  • Print
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Carol Bazell, Gabriela Dieguez, Christine Ferro | 08 April 2019

Secondary progressive multiple sclerosis (SPMS) is a disabling multiple sclerosis phenotype marked by relentlessly progressing neurologic disability. At the time of this analysis, there were no therapies approved by the Food and Drug Administration for SPMS with a manageable risk-benefit ratio. This paper examines the prevalence, demographics, and healthcare cost of SPMS patients.

This article was commissioned by Novartis Pharmaceuticals Corporation.

Authors